Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date

References

• RiesLASmithMAGurneyJGCancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975–1995BethesdaNational Cancer Institute1999179
   Google Scholar
• WardEDesantisCRobbinsAKohlerBJemalAChildhood and adolescent cancer statistics, 2014CA Cancer J Clin20146428310324488779
   PubMed Web of Science ®Google Scholar
• MalempatiSGaynonPSSatherHLaMKStorkLCChildren’s Oncology GroupOutcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children’s Oncology Group study CCG-1952J Clin Oncol200725365800580718089878
   PubMed Web of Science ®Google Scholar
• NguyenKDevidasMChildren’s Oncology GroupFactors influencing survival after relapse from acute lymphoblastic leukemia: a Children’s Oncology Group studyLeukemia200822122142215018818707
   PubMed Web of Science ®Google Scholar
• RoweJMECOG; MRC/NCRI Adult Leukemia Working PartyInduction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993Blood2005106123760376716105981
   PubMed Web of Science ®Google Scholar
• StockWJohnsonJLStoneRMDose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802Cancer20131191909822744771
   PubMed Web of Science ®Google Scholar
• BaeuerlePAReinhardtCBispecific T-cell engaging antibodies for cancer therapyCancer Res200969124941494419509221
   PubMed Web of Science ®Google Scholar
• Blincyto (blinatumomab) [package insert]Thousand Oaks, CAAmgen Inc2014
   Google Scholar
• ToppMSGökbugetNZugmaierGPhase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemiaJ Clin Oncol201432364134414025385737
   PubMed Web of Science ®Google Scholar
• ZugmaierGGökbugetNKlingerMLong-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatmentBlood2015126242578258426480933
   PubMed Web of Science ®Google Scholar
• KantarjianHSteinAGökbugetNBlinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic LeukemiaN Engl J Med2017376983684728249141
   PubMed Web of Science ®Google Scholar
• ToppMZimmermanZCannellPHealth-related quality of life in adults treated with blinatumomab using the acute lymphoblastic leukemia symptom scaleBlood2018131262906291429739753
   PubMed Web of Science ®Google Scholar
• MartinelliGBoisselNChevallierPComplete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter StudyJ Clin Oncol201735161795180228355115
   PubMed Web of Science ®Google Scholar
• ToppMSKuferPGökbugetNGoNTargeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survivalJ Clin Oncol201129182493249821576633
   PubMed Web of Science ®Google Scholar
• BrüggemannMRaffTGerman Multicenter Study Group for Adult Acute Lymphoblastic LeukemiaClinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemiaBlood200610731116112316195338
   PubMed Web of Science ®Google Scholar
• BurmeisterTMarschalekRSchneiderBMonitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrationsLeukemia200620345145716424875
   PubMed Web of Science ®Google Scholar
• CampanaDMinimal residual disease in acute lymphoblastic leukemiaHematology Am Soc Hematol Educ Program20102010171221239764
   PubMed Web of Science ®Google Scholar
• BargouRLeoEZugmaierGTumor regression in cancer patients by very low doses of a T cell-engaging antibodyScience2008321589197497718703743
   PubMed Web of Science ®Google Scholar
• GökbugetNDombretHBonifacioMBlinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemiaBlood2018131141522153129358182
   PubMed Web of Science ®Google Scholar
• von StackelbergALocatelliFZugmaierGPhase I/Phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemiaJ Clin Oncol201634364381438927998223
   PubMed Web of Science ®Google Scholar
• FreyNVPorterDLCytokine release syndrome with novel therapeutics for acute lymphoblastic leukemiaHematology Am Soc Hematol Educ Program20162016156757227913530
   PubMed Web of Science ®Google Scholar
• WangZHanWBiomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapyBiomark Res201861429387417
   PubMed Web of Science ®Google Scholar
• DeleaTEAmdahlJBoykoDCost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome- negative B-precursor acute lymphoblastic leukemia from a US payer perspectiveJ Med Econ201720991192228631497
   PubMed Web of Science ®Google Scholar
• KantarjianHMDeangeloDJStelljesMInotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic LeukemiaN Engl J Med2016375874075327292104
   PubMed Web of Science ®Google Scholar
• NagorsenDBaeuerlePAImmunomodulatory therapy of cancer with T-cell-engaging BiTE antibody blinatumomabExp Cell Res201131791255126021419116
   PubMed Web of Science ®Google Scholar
• National Cancer InstituteBlinatumomab and nivolumab with or without ipilimumab in treating patients with poor-risk relapsed or refractory CD19+ precursor B-lymphoblastic leukemia Available from: https://clinicaltrials.gov/ct2/show/NCT02879695Accessed September 14, 2018
   Google Scholar
• WieduwiltMBlinatumomab and pembrolizumab for adults with relapsed/refractory B-cell acute lymphoblastic leukemia with high marrow lymphoblasts Available from: https://clinicaltrials.gov/ct2/show/NCT03160079Accessed September 14, 2018
   Google Scholar
• University of California, DavisIbrutinib and blinatumomab in treating patients with relapsed or refractory B acute lymphoblastic leukemia Available from: https://clinicaltrials.gov/ct2/show/NCT02997761Accessed September 14, 2018
   Google Scholar
• National Cancer InstituteCombination chemotherapy with or without blinatumomab in treating patients with newly diagnosed BCR-ABL-negative B lineage acute lymphoblastic leukemia Available from: https://clinicaltrials.gov/ct2/show/NCT02003222Accessed September 14, 2018
   Google Scholar